GlaxoSmithKline to spend $5.1B on cancer drugmaker Tesaro
Shares of Tesaro soared early Monday after GlaxoSmithKline said it would pay about $5.1 billion in cash to buy the cancer drugmaker. Glaxo plans to pay $75 per share for Tesaro, which makes the ovarian cancer treatment Zejula.
from Biotech News
0 Comments